The effect of SARS-CoV-2 vaccination on post-acute COVID-19 syndrome (PASC): A prospective cohort study 8 261 Supplementary Figure S2. IgG binding and spike neutralisation at 30-60 days following illness onset among participants with moderate COVID-19 who did (N = 32) and did not develop (N = 33) PASC Association between 30-60 day WT-D614G spike protein neutralising IgG titers and anti-S and antiRBD IgG binding titers and consequent development of PASC among those with moderate COVID-19. The mean effects were estimated using a Bayesian multilevel model. Differences in posterior means were mean-centred such that effect sizes shown can be compared on a common scale (top row). Distributions of serum spike protein neutralising IgG titers (bottom left), spike binding (bottom middle) and RBD binding (bottom right) displayed such that each dot represents one participant.
RkJQdWJsaXNoZXIy MTk4NDMw